In the past week, GMED stock has gone down by -23.05%, with a monthly decline of -25.50% and a quarterly plunge of -36.85%. The volatility ratio for the week is 2.12%, and the volatility levels for the last 30 days are 3.12% for Globus Medical Inc The simple moving average for the past 20 days is -21.91% for GMED’s stock, with a -28.07% simple moving average for the past 200 days.
Is It Worth Investing in Globus Medical Inc (NYSE: GMED) Right Now?
Globus Medical Inc (NYSE: GMED) has a price-to-earnings ratio that is above its average at 41.39x. The stock has a 36-month beta value of 1.30. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for GMED is 111.93M, and at present, short sellers hold a 3.79% of that float. On May 09, 2025, the average trading volume of GMED was 1.25M shares.
GMED) stock’s latest price update
The stock price of Globus Medical Inc (NYSE: GMED) has dropped by -23.63 compared to previous close of 72.46. Despite this, the company has seen a fall of -23.05% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-08 that Globus Medical, Inc. (NYSE:GMED ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Kearns – SVP, Business Development & IR Dan Scavilla – President & CEO Keith Pfeil – COO & CFO Conference Call Participants Matt Miksic – Barclays Vik Chopra – Wells Fargo Richard Newitter – Truist Securities Matthew Blackman – Stifel Shagun Singh – RBC Caitlin Cronin – Canaccord Genuity David Saxon – Needham & Company Craig Bijou – Bank of America Merrill Lynch Matt Taylor – Jefferies Operator Welcome to the Globus Medical’s First Quarter 2025 Earnings Call. [Operator Instructions].
Analysts’ Opinion of GMED
Many brokerage firms have already submitted their reports for GMED stocks, with BofA Securities repeating the rating for GMED by listing it as a “Neutral.” The predicted price for GMED in the upcoming period, according to BofA Securities is $97 based on the research report published on January 10, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see GMED reach a price target of $100, previously predicting the price at $83. The rating they have provided for GMED stocks is “Overweight” according to the report published on December 02nd, 2024.
Wells Fargo gave a rating of “Overweight” to GMED, setting the target price at $78 in the report published on August 07th of the previous year.
GMED Trading at -23.86% from the 50-Day Moving Average
After a stumble in the market that brought GMED to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.71% of loss for the given period.
Volatility was left at 3.12%, however, over the last 30 days, the volatility rate increased by 2.12%, as shares sank -22.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.05% lower at present.
During the last 5 trading sessions, GMED fell by -23.47%, which changed the moving average for the period of 200-days by -25.00% in comparison to the 20-day moving average, which settled at $70.84. In addition, Globus Medical Inc saw -33.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GMED starting from RHOADS ANN D, who sale 7,500 shares at the price of $78.68 back on Feb 28 ’25. After this action, RHOADS ANN D now owns 35,384 shares of Globus Medical Inc, valued at $590,100 using the latest closing price.
RHOADS ANN D, the Director of Globus Medical Inc, proposed sale 7,500 shares at $78.67 during a trade that took place back on Feb 28 ’25, which means that RHOADS ANN D is holding shares at $590,000 based on the most recent closing price.
Stock Fundamentals for GMED
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.55 for the gross margin
The net margin for Globus Medical Inc stands at 0.04. The total capital return value is set at 0.05. Equity return is now at value 4.63, with 3.84 for asset returns.
Based on Globus Medical Inc (GMED), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at 0.97. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is 42.89.
Currently, EBITDA for the company is 378.94 million with net debt to EBITDA at -0.48. When we switch over and look at the enterprise to sales, we see a ratio of 2.92. The receivables turnover for the company is 4.36for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.45.
Conclusion
To sum up, Globus Medical Inc (GMED) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
